Archive

  • Comment - What future for PE-backed life book consolidators as AXA and Athora ditch transfer plans?

    07 May 2024

    Ending it was consensual, but BaFin was surely in the deal-partners' thoughts

  • SFCRs shine light on German legacy life books, and investments, of Zurich and AXA

    16 April 2024

    Groups have planned, with mixed success, to sell the back-books to consolidators Viridium and Athora, respectively

  • Chart of the Week - How hiccups emerged in property risk-taking in Swiss Life's business

    29 March 2024

    Swiss Life's recent annual results showed how problematic property investments can be for insurers these days

  • Chart of the Week - How IMAs could spell out the future of PE ownership of insurers

    23 February 2024

    Fee rates, and other T&Cs in the IMAs of PE houses and the consolidators they own, may attract (unwanted) regulatory attention

  • BaFin survey reveals fund manager dissatisfaction with ESG data

    15 February 2024

    German regulator found prices too high, transparency questionable and quality checks too variable

  • Achmea not ruling out offloading life and pensions business - worth €21.9bn of general account

    12 February 2024

    Deal would involve group transferring up to 60% of its general account assets

  • Chart of the Week - As a €21bn deal is scuppered by BaFin, have PE owners run out of road for life book sales?

    02 February 2024

    German regulator's refusal to Zurich and Viridium seems bad news for insurers owned by PE

  • German backbook deals and run-offs - a €150bn asset industry since 2014

    01 February 2024

    Moody's examined 14 deals, completed, pending and scuttled

  • Comment - BaFin holds cards (close to its chest) in future of German life-book consolidation

    01 February 2024

    PE part-ownership of Viridium seems to have informed regulator's rejection of Zurich deal

  • Comment - Are PE owners facing the end of their life backbook consolidation journey?

    31 January 2024

    After BaFin's move on Zurich and Viridium, the future seems uncertain if 'PE ownership' breaks deals